Home > Publications Database > Toward a biological definition of neuronal and glial synucleinopathies. > print

001     276802
005     20250323000849.0
024 7 _ |a 10.1038/s41591-024-03469-7
|2 doi
024 7 _ |a pmid:39885358
|2 pmid
024 7 _ |a 1078-8956
|2 ISSN
024 7 _ |a 1546-170X
|2 ISSN
024 7 _ |a altmetric:173635728
|2 altmetric
037 _ _ |a DZNE-2025-00327
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Soto, Claudio
|0 0000-0002-3412-0524
|b 0
245 _ _ |a Toward a biological definition of neuronal and glial synucleinopathies.
260 _ _ |a [New York, NY]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1742207129_2880
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cerebral accumulation of alpha-synuclein (αSyn) aggregates is the hallmark event in a group of neurodegenerative diseases-collectively called synucleinopathies-which include Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Currently, these are diagnosed by their clinical symptoms and definitively confirmed postmortem by the presence of αSyn deposits in the brain. Here, we summarize the drawbacks of the current clinical definition of synucleinopathies and outline the rationale for moving toward an earlier, biology-anchored definition of these disorders, with or without the presence of clinical symptoms. We underscore the utility of the αSyn seed amplification assay to detect aggregated αSyn in living patients and to differentiate between neuronal or glial αSyn pathology. We anticipate that a biological definition of synucleinopathies, if well-integrated with the current clinical classifications, will enable further understanding of the disease pathogenesis and contribute to the development of effective, disease-modifying therapies.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a alpha-Synuclein
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neuroglia: pathology
|2 MeSH
650 _ 2 |a Neuroglia: metabolism
|2 MeSH
650 _ 2 |a alpha-Synuclein: metabolism
|2 MeSH
650 _ 2 |a alpha-Synuclein: genetics
|2 MeSH
650 _ 2 |a Synucleinopathies: pathology
|2 MeSH
650 _ 2 |a Synucleinopathies: metabolism
|2 MeSH
650 _ 2 |a Neurons: pathology
|2 MeSH
650 _ 2 |a Neurons: metabolism
|2 MeSH
650 _ 2 |a Parkinson Disease: pathology
|2 MeSH
650 _ 2 |a Parkinson Disease: genetics
|2 MeSH
650 _ 2 |a Parkinson Disease: metabolism
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Multiple System Atrophy: pathology
|2 MeSH
650 _ 2 |a Multiple System Atrophy: metabolism
|2 MeSH
650 _ 2 |a Multiple System Atrophy: genetics
|2 MeSH
650 _ 2 |a Lewy Body Disease: pathology
|2 MeSH
650 _ 2 |a Lewy Body Disease: metabolism
|2 MeSH
650 _ 2 |a Lewy Body Disease: genetics
|2 MeSH
700 1 _ |a Mollenhauer, Brit
|0 P:(DE-2719)9001340
|b 1
|u dzne
700 1 _ |a Hansson, Oskar
|0 0000-0001-8467-7286
|b 2
700 1 _ |a Kang, Un Jung
|0 0000-0002-5970-6839
|b 3
700 1 _ |a Alcalay, Roy N
|0 0000-0002-5717-4875
|b 4
700 1 _ |a Standaert, David
|0 0000-0003-2921-8348
|b 5
700 1 _ |a Trenkwalder, Claudia
|0 0000-0001-6407-1199
|b 6
700 1 _ |a Marek, Kenneth
|b 7
700 1 _ |a Galasko, Douglas
|b 8
700 1 _ |a Poston, Kathleen
|0 0000-0003-3424-7143
|b 9
773 _ _ |a 10.1038/s41591-024-03469-7
|g Vol. 31, no. 2, p. 396 - 408
|0 PERI:(DE-600)1484517-9
|n 2
|p 396 - 408
|t Nature medicine
|v 31
|y 2025
|x 1078-8956
856 4 _ |u https://pub.dzne.de/record/276802/files/DZNE-2025-00327_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/276802/files/DZNE-2025-00327_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:276802
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9001340
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a DEAL Nature
|0 StatID:(DE-HGF)3003
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT MED : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-06
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-06
915 _ _ |a IF >= 80
|0 StatID:(DE-HGF)9980
|2 StatID
|b NAT MED : 2022
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21